ClinicalTrials.gg

Program

bexicaserin

Also written as “LP352” and “LP352, bexicaserin”.

Its studies are mostly in Epilepsies, Myoclonic · Seizures, led by H. Lundbeck.

Furthest: phase 3, since Oct 24, 20245 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeck53 open or runningphase 3since Oct 24, 2024Mar 22, 2022Dec 31, 2026phase 3 · NCT06660394

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2022First study: phase 2 study in Epilepsies, MyoclonicFirst studyNCT05364021 · 52 enrolled · United States, Australia
  2. Nov 15, 2022Phase 2 study in Epilepsies, MyoclonicNCT05626634 · 41 enrolled · United States, Australia
  3. Oct 24, 2024Phase 3 study in Epilepsies, MyoclonicNCT06660394 · 108 enrolled · United States, Australia, Belgium and more
  4. Dec 2, 2024Phase 3 study in SeizuresNCT06719141 · 367 enrolled · United States, Australia, Belgium and more
  5. Mar 6, 2025Phase 3 study in SeizuresNCT06908226 · 324 planned · United States, Australia, Belgium and more

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Epilepsies, MyoclonicNCT06660394
  2. Nov 11, 2027Primary completion: phase 3 study in SeizuresNCT06908226

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06908226Seizures · United States, Australia, Belgium and more3By invitationNov 11, 2027324
NCT06719141Seizures · United States, Australia, Belgium and more3Active, not recruitingOct 31, 2026367
NCT06660394Epilepsies, Myoclonic · United States, Australia, Belgium and more3Active, not recruitingDec 31, 2026108
NCT05626634Epilepsies, Myoclonic · United States, Australia2CompletedDec 20, 202441
NCT05364021Epilepsies, Myoclonic · United States, Australia2CompletedNov 16, 202352

How it is read

Names in the registry

  • “LP352”, 4 entries
  • “LP352, bexicaserin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.